-
Sales of parasite treatments on the rise
Each year, as many as 12 million sets of parents come home to find their children frantically scratching their heads due to a head lice infestation. And that incidence appears to be on the rise, as sales of parasite treatments were up 7.3% to $163.7 million for the 52 weeks ended May 15 across total U.S. multi-outlets, according to IRI data.
-
Flonase continues market strength
GSK Consumer Healthcare’s Flonase allergy remedy was the single greatest generator of incremental dollars for the 52 weeks ended May 15 across total U.S. multi-outlets, according to IRI data, with $345.2 million in sales on 209.9% growth. The question headed into its second year on OTC shelves is can it maintain its momentum now that private-label competition for Flonase has reached store shelves.